Core Viewpoint - China Medical System Holdings Limited (CMS) has received approval from the National Medical Products Administration (NMPA) for its new drug Desidustat Tablets, aimed at treating renal anaemia in non-dialysis adult Chronic Kidney Disease (CKD) patients [1][2]. Group 1: Product Approval and Market Impact - The approval of Desidustat Tablets enhances CMS's positioning in the nephrology sector and complements its existing product, Velphoro, which treats CKD hyperphosphatemia [2]. - CMS anticipates rapid clinical application of Desidustat Tablets through effective resource linkage and channel networks, aiming to provide differentiated treatment options for CKD patients in China [2]. Group 2: Clinical Efficacy and Unmet Needs - Desidustat Tablets function as a novel oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI), promoting erythropoiesis by increasing endogenous erythropoietin and improving iron availability [3]. - Clinical trials in China have shown that Desidustat significantly increases haemoglobin levels compared to placebo, with long-term studies indicating it can maintain target haemoglobin levels safely [3]. - There is a significant unmet need for effective anaemia treatments in CKD patients, with over 120 million CKD patients in China and low treatment compliance rates among non-dialysis patients [4]. Group 3: Strategic Focus and Innovation - CMS follows an "innovation-driven" strategy, with a diverse product portfolio that includes 7 approved drugs and nearly 20 projects in clinical trials [6]. - The company aims to enhance its innovative pipeline with first-in-class and best-in-class products, focusing on clinical needs to deliver quality pharmaceutical solutions [6][8]. - CMS is committed to expanding its operations in specialty therapeutic fields, including cardiovascular, kidney, metabolic, gastroenterology, ophthalmology, and skin health, to strengthen its market position [9].